Accumark Labs

CERTIFICATE OF ANALYSIS

Valor Peptides

SAMPLE NAME:	Tesamorelin
SAMPLE CODE:	GZV4-9TSJ
RECEIVED DATE:	09/21/2026
PUBLISHED DATE:	09/24/2026

DECLARED IDENTITY	Tesamorelin
MATRIX TYPE:	PEPTIDE
SAMPLE NAME:	Tesamorelin
SAMPLE SIZE:	10.0 mg
№ LOT CODE:	ARC-TS10-015

10.134 mg
Total Quantity

99.39%
Total Blend Purity

Sample	Test	Specification	Result	Status
Tesamorelin	IDENTITY	Tesamorelin	Tesamorelin	CONFORMS
Tesamorelin	QUANTITY	MEASURE	10.134 mg	MEASURED
Tesamorelin	PURITY	> 98.0%	99.39%	CONFORMS

HPLC Chromatogram Report



RESULTS REVIEWED BY:

Anthony Burke PhD
Lab Manager
09/24/2026

RESULTS CERTIFIED BY:

Dr. Levi Fried MD
Lab Director
09/24/2026

ACCUMARKLABS.COM
GZV4-9TSJ
09/24/2026

Accumark Labs

CERTIFICATE OF ANALYSIS

Valor Peptides

SAMPLE NAME:	Tesamorelin
SAMPLE CODE:	GZV4-9TSJ
RECEIVED DATE:	09/21/2026
PUBLISHED DATE:	09/24/2026

Endotoxin USP85 LAL

Test	Specification (EU/mL)	Result (EU/mL)	LOQ (EU/mL)	Verdict
Endotoxin USP85 LAL	≤5	< LOQ	2.5	**Conforms**

Method: Endotoxin testing performed using Limulus Amebocyte Lysate assay in accordance with USP <85> under validated laboratory conditions.

Rapid Sterility Screening (PCR)

Test	Specification	Result	Unit	Verdict
Rapid Sterility Screening (PCR)	Not Detected	Not Detected		**Conforms**

Method: Rapid sterility screening performed by real-time polymerase chain reaction (qPCR) targeting conserved microbial DNA sequences under validated laboratory conditions.

Heavy Metals - Elemental Impurities

Basis: USP<232> Parenteral PDE | Assumed MDD 25mg / day

Test	Specification (µg/g)	Result (µg/g)	LOQ (µg/g)	Verdict
Lead	≤ 200	< LOQ	3.2	**Conforms**
Arsenic	≤ 600	< LOQ	55	**Conforms**
Cadmium	≤ 80	< LOQ	40	**Conforms**
Mercury	≤ 120	< LOQ	40	**Conforms**

Method: MP-AES | Sample Prep: Hot block acid digestion of 100 mg of sample with concentrated nitric acid and hydrogen peroxide, loosely capped, diluted to 10 mL.

Basis: Elemental impurity limits are derived from the USP<232> parenteral permitted daily exposure values converted to a concentration basis at the stated maximum daily dose.
Assumed MDD: Concentration limits are derived from the USP<232> parenteral permitted daily exposures — As 15 µg/day, Cd 2 µg/day, Hg 3 µg/day, Pb 5 µg/day — at an assumed maximum daily dose of 25 mg of total drug product (API plus excipient)/day, giving specification limits of As 600 µg/g, Cd 80 µg/g, Hg 120 µg/g, and Pb 200 µg/g. Limits scale inversely with dose; products administered above the assumed MDD require proportionally lower concentration limits.

Fentanyl Screening

Basis: Qualitative lateral-flow immunoassay | Strip detection threshold 200 ng/mL in prepared solution

Test	Specification	Result	Unit	Verdict
Fentanyl	Not Detected	Not Detected		**Conforms**

Method: Lateral-flow immunoassay test strip | Sample Prep: Aqueous reconstitution prepared ; test strip immersed directly per manufacturer procedure

Reporting Fentanyl screening is qualitative. Results are reported as Not Detected or Detected relative to the test strip's stated detection threshold; no numeric concentration is measured or implied. Not Detected indicates fentanyl was not present above that threshold in the prepared sample solution.

RESULTS CERTIFIED BY:

Anthony Burke PhD
Lab Manager
09/24/2026

RESULTS CERTIFIED BY:

Dr. Levi Fried MD
Lab Director
09/24/2026

ACCUMARKLABS.COM
GZV4-9TSJ
09/24/2026